On the other hand, Press et al (2002) evaluated CB11 expression (anti-ERBB2 antibody approved by FDA for clinical testing) (Press et al, 1994; Felip et al, 1995; Van der Zee et al, 1995; Bookman et al, 2003) in tumours with determined ERBB2 gene amplification and mRNA expression, and found better CB11 sensitivity and accuracy for staining categories 1+ to 3+ than for 2+ and 3+ alone; the specificity was similar (98.6 vs 100%, respectively). This evidence concerns the gene ERBB2 and neoplasm.